The Bluhm Cardiovascular Institute of Northwestern Memorial Hospital recently implanted a patient with two of the smallest experimental ventricular assist devices (VADs) currently available for study in humans.
VADs are designed to assist either the right (RVAD) or left (LVAD) ventricle, or both (BiVAD) at once. This is the first time that two Heartware™ VADs have been implanted in the left and right ventricles anywhere in North America—a “game changer” in the realm of heart assist devices according to Patrick M. McCarthy, MD, chief of the hospital’s Division of Cardiac Surgery and director of the hospital’s Bluhm Cardiovascular Institute.
“The world doesn’t need the artificial heart anymore,” said Dr. McCarthy, who is also the Heller-Sacks Professor of Surgery at Northwestern University Feinberg School of Medicine. “The goal is total support of the heart. This biventricular approach achieves that without cutting out the patient’s own heart, which is what happens with artificial heart implants.”
According to Edwin C. McGee, Jr. MD, surgical director for the Bluhm Institute’s Heart Transplant and Assist Device program and the lead cardiac surgeon who performed the implant, when the patient, 44-year-old James Armstrong, was transferred to Northwestern Memorial just weeks ago, he was near death with an aggressive state of myocarditis. Myocarditis is a severe inflammation of the heart tissue that—in some rare cases—can be fatal when unaddressed.
Only about a dozen times before in Europe had the twin implant of the small Heartware™ VAD been performed, and now the approach would be Armstrong’s best chances for survival. The Heartware™ VAD is under trial in the U.S. as an LVAD. Mr. Armstrong did not qualify for the current trial and was able to have the device implanted under a process known as “emergency use”. Emergency use is defined as the use of an investigational article with a human subject in a life-threatening situation. Although such uses are not yet approved by the U.S. Food and Drug Administration, they are allowed when there is no standard acceptable treatment available and there is not sufficient time to obtain approval from an Institutional Review Board.
“As we do for all of our patients, we wanted the very best for Jim,” said McGee. “Standard BiVAD pumps sit outside of the body and are plagued by an extremely high complication and mortality rate.”
McGee added that another reason to study this system is because the configuration leaves patients’ hearts intact. This, he says, lends itself to the possibility that in some rare cases the heart may actually recover. “Naturally, that remains to be seen—but it’s possible,” he says. This probability is obliterated with artificial hearts because essential components of the natural heart are removed.
McGee adds that one of the greatest advantages to patients is that the pumps are contained (implanted) completely within the chest. There are two small controlling leads in the body that connect to a small monitor and power source outside the body that can be carried in two small shoulder pouches.
“Using this device in a biventricular support configuration may offer total heart support to more individuals with improved quality of life and hopefully fewer complications, than with the currently approved devices,” added McGee.
The American Heart Association estimates that an average of 300,000 people die every year from heart failure—and roughly 10,000 of them qualify for heart transplant. Due to lack of donor organs roughly only 2000 cardiac transplants are performed each year. Assist devices such as the ones Armstrong received are becoming an increasingly important therapy to help individuals with advanced heart failure.
Dr. McGee is a paid consultant for HeartWare™.Media Contact
Kris Lathan | EurekAlert!
Münster researchers make a fly’s heartbeat visible / Software automatically recognizes pulse
12.03.2018 | Westfälische Wilhelms-Universität Münster
3-D-written model to provide better understanding of cancer spread
05.03.2018 | Purdue University
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Life Sciences
23.03.2018 | Materials Sciences
23.03.2018 | Process Engineering